hyaluronic acid + doxorubicin

**hyaluronic acid + doxorubicin** is a combination drug formulation in which the chemotherapeutic agent **doxorubicin** is complexed with or encapsulated by **hyaluronic acid**. This system is designed as a *polymer-drug conjugate therapy* or as *nanoparticles*, offering targeted delivery to tumors that overexpress hyaluronic acid receptors (mainly CD44)[2][4][5]. Doxorubicin acts primarily by intercalating DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis in cancer cells. Hyaluronic acid serves as both a biocompatible carrier and a ligand for CD44, ensuring enhanced tumor targeting, increased intracellular drug accumulation, and reduced systemic toxicity[2][4][5]. The combination exploits the natural affinity of hyaluronic acid for CD44 on tumor cells for selective delivery, and the formulation is often engineered to have pH-sensitive release, favoring drug release in the acidic tumor microenvironment[4][5]. Developers and formulations vary widely in research and may involve academic labs or research hospitals rather than specific commercial companies.

Other names

hyaluronic acid-doxorubicinHA-DoxHA-Dox nanoparticlesHA-doxorubicin conjugate